The development of novel agents targeting BCMA is ongoing rapidly, especially following impressive clinical responses in relapsed MM patients using the first chimeric antigen receptor (CAR) T cell therapy (78). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.